This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
GLOSTRUP, Denmark, July 7, 2014 (GLOBE NEWSWIRE) --
Dako, an Agilent Technologies company andaworldwide provider of cancer diagnostics, today announced positive findings in a white paper by ProPath Servicescomparing Dako's HER2 IQFISH pharmDx(TM) kit with Abbott's PathVysion HER-2 DNA Probe kit.
ProPath Services is an independent anatomic pathology laboratory headquartered in Dallas, Texas. The white paper, written by Debra S. Cohen, BS, CG(ASCP)
CM and Sharon Alsobrook, CG(ASCP)
CM, is based on ProPath's comprehensive, eight-month study of 1,500 formalin-fixed, paraffin-embedded tissue sections.
The white paper highlights the major advantages customers experience by using Dako's
HER2 IQFISH pharmDx
TM kit, which uses the revolutionary, fast-hybridization IQFISH buffer. The authors found that
HER2 IQFISH pharmDx
TM provided better overall quality than the PathVysion kit, defined by better signal-to-background ratio enabling more accurate determination of copy numbers. The study also concluded that the Dako kit saved 30-60 minutes of hands-on time per slide, due to less hands-on time required by lab staff, and reduced time required by the pathologist for reading and scoring. The paper highlights cost savings achieved through fewer slide repeats required. Finally, the study showed that the short turnaround time for IQFISH resulted in almost three times more diagnoses reported within a day or less.
Dako introduced the groundbreaking IQFISH hybridization buffer chemistry in 2012. The IQFISH buffer reduces test turnaround time from 17 hours to just 3.5 hours. In addition, it avoids the use of toxic formamide in assays and eliminates concerns for pregnant laboratory technicians. The buffer is environmentally friendly and does not require a fume hood during use (1).
Nearly one million new cases of gastric cancer and more than 1.5 million new cases of breast cancer are diagnosed each year worldwide (2). As an aid in the treatment decision,
HER2 IQFISH pharmDx(TM) can quantitatively determine
HER2 gene amplification in the tumor, allowing oncologists to prescribe potentially life-saving therapies to patients quickly and effectively.
Matthiesen, S. H. and C. M. Hansen. Fast and non-toxic in situ hybridization without blocking of repetitive sequences. PLoS One 2012; 7:1-7 (e40675).
Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray, F. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. Available from: http://globocan.iarc.fr, accessed on 24/January/2014.
About Agilent Technologies
Agilent Technologies Inc. (NYSE:A) is the world's premier measurement company and a technology leader in chemical analysis, life sciences, diagnostics, electronics and communications. The company's 20,600 employees serve customers in more than 100 countries. Agilent had revenues of $6.8 billion in fiscal 2013. Agilent acquired Dako in 2012, a well-known provider of reagents, instruments, software and expertise to make accurate diagnoses and determine the most effective treatment for cancer patients. Information about Agilent is available at
www.agilent.com and information about Dako products is available at
On Sept. 19, 2013, Agilent announced plans to separate into two publicly traded companies through a tax-free spinoff of its electronic measurement business. The new company is named Keysight Technologies, Inc. The separation is expected to be completed in early November 2014.